Navigation Links
Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
Date:2/6/2008

Effort is Launched With UC Davis Collaboration

RANCHO CORDOVA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury, today announced a regenerative medicine initiative in the veterinary market.

The Company has created a wholly-owned subsidiary, Vantus, Inc., a veterinary stem cell laboratory services company. The Company is in the process of completing a research collaboration with the Center for Equine Health and Stem Cell Regenerative Medicine Group at the University of California, Davis, School of Veterinary Medicine.

Under the collaboration, the Company's MarrowXpress(TM) System and BioArchive(R) System will be used for the processing and cryogenic storage of equine stem cells from cell rich sources, including fetal tissue and fluids during foaling, and bone marrow from yearlings and adults. The stem cells will be used in therapeutic treatment of orthopedic injuries in the performance equine market including Thoroughbreds, American Quarter Horses, and Arabians. The Company is currently refining collection and processing methodologies at large breeder farms in California, and expects to be in operation commencing with the 2009 foaling season, which begins in January of next year.

"The creation of Vantus, Inc. is a major milestone in our regenerative medicine diversification strategy that we began implementing several months ago. This program leverages the expertise and world renowned reputation of the UC Davis organization in animal research and our industry leading stem cell processing and storage technologies," noted Dr. William Osgood, Chief Executive Officer of ThermoGenesis.

"We have the potential to create a new paradigm for the treatment of injured performance horses using our unique approach of capturing stem cells when the horse is born up through the first year of life. This represents a potentially sizeable market opportunity for the Company in which we believe we can achieve a meaningful competitive advantage quickly. Equine stem cells are being used successfully to treat a number of injuries today, with the potential for significant and rapid growth given the early clinical efficacy of these treatments and relatively low regulatory hurdles in the veterinary market," he added.

"The collaborative support and assistance we will be receiving from Vantus should allow our scientists to move forward rapidly in the development of new and unique veterinary stem cell applications. We expect that their experience in the processing and bioarchival storage of stem cells, combined with the expertise of our research and clinical personnel, will provide compelling synergy for scientific discovery," said Dr. Gregory Ferraro, of the UC Davis Center for Equine Health.

Osgood noted, "In addition, the experience we gain in the veterinary stem cell market and the products and services that will come from research and innovations in harvesting, processing, and therapeutic treatments, will directly translate to treatment of human orthopedic injury and disease and speed our entry into this evolving market."

"Finally, we believe our wound healing technologies will have direct application in the veterinary market, which we expect will add additional revenues to the Company," he added.

To learn more about Vantus please log onto http://www.vantuslabs.com.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com) is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by

cord blood stem cell banks in more than 25 countries for cryopreserving

and archiving cord blood stem cell units for transplant. GE Healthcare

is the nonexclusive global distribution partner for the BioArchive

System.

-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of

automated devices that includes the AXP and the MarrowXpress(TM) and

companion sterile blood processing disposable for harvesting stem cells

in a closed system. The AXP device is used for the processing of cord

blood. GE Healthcare is the exclusive global distribution partner for

the AXP cord blood product. The MarrowXpress is used for isolating stem

cells from bone marrow. ThermoGenesis sells the MarrowXpress directly

to global customers.

-- The CryoSeal(R) FS System, an automated device and companion sterile

blood processing disposable, is used to prepare fibrin sealants from

plasma in about an hour. We received FDA approval to market the

CryoSeal FS System in liver resection surgeries in July 2007. The

CryoSeal FS System has received the CE-Mark. From a marketing

perspective, the CE Mark is the European equivalent to an FDA approval,

in that it allows sales of the product throughout the European

community. Asahi Medical is the exclusive distributor for the CryoSeal

System in Japan and the Company markets through independent

distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood

processing disposable that prepares activated thrombin from a small

aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

currently being marketed in Europe by Biomet, Inc., subsidiary Biomet

Biologics, Medtronic, Inc. and independent distributors.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Corp. Reports First Quarter 2008 Results
2. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
3. Zipfizz(R) Announces Expanded Distribution
4. Mangrove Announces Health Savings Account (HSA) and Health Reimbursement Account (HRA) Product Launches
5. Senetek PLC Announces Launch of New Website
6. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
7. Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008
8. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
9. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
10. The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application
11. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic dentist ... whitening is among the most popular cosmetic procedures in dentistry today, but the cost ... can put them at risk of teeth whitening-related damage. For a limited time, Dr. ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... ... 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of ... GRIP-DRY is a newly patented product that has solved some of the basic problems golfers ... early morning dew or right after a rain shower, might understand the struggle of placing ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... with BASF Human Nutrition into the Food & Beverage and ... been BASF’s channel partner throughout Canada and USA geographies east of the Rocky ...
(Date:2/8/2016)... Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has struggled ... of Freedom Laser Therapy , was determined to find solutions to his problems – ... of Inventors Digest is ready to introduce his breakthrough inventions to the world ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... The new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 ... that the North America continued to lead ... that translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... global anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... , Feb.8, 2016 Alzheimer Diagnostic ... Summary Medical Devices sector report , ... 2015" provides an overview of Alzheimer Diagnostic Tests ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
(Date:2/8/2016)... , Feb. 8, 2016  Labvantage Lx, a ... its first male sexual enhancement product, EnduramenT. Setting ... proven ethnobotanicals with a patented biomedical breakthrough molecule ... the chemical compound responsible for many biological functions ... Forgoing the use of prescription ...
Breaking Medicine Technology: